Noradrenalin versus Midodrin-Octerotid in Hepatorenal Syndrome

Noradrenalin versus the combination of Midodrine and Octreotide in the treatment of patients with Hepatorenal syndrome type 1 and 2 referred to Alzahra Hospital since 2011 to 2012

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201107217085N1

Enrollment

Registered

2011-11-22

Start date

2011-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatorenal Syndrome type 1 & 2. Hepatorenal Syndrome

Interventions

Intervention 1: One group is treated with Noradrenalin infusion of 0.1 microgram per kilogram. The dose is escalated every 4 hours by 0.05 microgram per kilogram up to the maximum dose of 0.7 microgra

Treatment - Drugs

One group is treated with Noradrenalin infusion of 0.1 microgram per kilogram. The dose is escalated every 4 hours by 0.05 microgram per kilogram up to the maximum dose of 0.7 microgram per kilogram o

The other group is treated with Octereotide infusion of 25 microgram per hour and oral Midodrin of 5 milligram three times a day up to the maximum dose of 45 milligram per day or until Mean arterial p

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Hepatorenal syndrom patients … Exclusion criteria: Improvement of renal function after volume expansion; history of infection, nephrotoxic drug usage or volume loss in recent week; contraindication to Noradrenalin, Midodrine or Octreotide; recent history of gastrointestinal bleeding; severe hepatic encephalopathy; hepatocellular carcinoma; platelet counts lower than 25000 per microliters; international normalized ratio (INR) more than 5; acute coronary syndrome

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Serum ceatinine. Timepoint: Before the study and every day during the study. Method of measurement: laboratory method.	—

Secondary

Measure	Time frame
Systolic and diastolic pressure. Timepoint: Before the study and every 4 hours during the study. Method of measurement: sphygmomanometer.;Urinary output. Timepoint: Before the study and every day during the study. Method of measurement: Collecting scaled bag.;Serum and urinary sodium. Timepoint: Before the study and every day during the study. Method of measurement: Laboratory method.;Glomerular filtration rate. Timepoint: Before the study and every day during the study. Method of measurement: Cockroft-Gault formula.	—

Measure

Time frame

Systolic and diastolic pressure. Timepoint: Before the study and every 4 hours during the study. Method of measurement: sphygmomanometer.;Urinary output. Timepoint: Before the study and every day during the study. Method of measurement: Collecting scaled bag.;Serum and urinary sodium. Timepoint: Before the study and every day during the study. Method of measurement: Laboratory method.;Glomerular filtration rate. Timepoint: Before the study and every day during the study. Method of measurement: Cockroft-Gault formula.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactKambiz Yazdanpanah

Isfahan University of Medical Sciences

kyazdanpanah@resident.mui.ac.ir+98 31 1669 4894

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026